Were you or a loved one diagnosed with Cutaneous T-Cell Lymphoma (CTCL) after taking Dupixent (dupilumab)? Our firm is reviewing potential lawsuits for patients who developed lymphoma and other serious side effects linked to this widely prescribed biologic. These cases allege that Dupixent can trigger or accelerate rare blood cancers, including CTCL, and that the drug manufacturers failed to provide adequate warnings about those risks.
Over the last several years, dermatologists and immunologists have reported a pattern that should give any responsible manufacturer pause. A subset of patients started Dupixent for what everyone thought was routine atopic dermatitis, only to be diagnosed with cutaneous T-cell lymphoma.
What follows is a clear-eyed examination of the medical literature, the regulatory record, and the litigation posture, written for victims and lawyers who seek analysis (rather than a law firm telling you how great they are). So our goal here is to explain how our lawyers evaluate these cases, where the science is moving, which defenses you can expect, and what it will take to prove causation and damages in a courtroom. We also talk about potential Deupxient settlement amounts if this litigation is as successful as we predict.